Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Inflaming the microenvironment of colorectal cancer to enable immunotherapy

Objective

Microsatellite-stable colorectal cancer (MSS CRC) accounts for 85–90% of CRCs and remains largely resistant to immune checkpoint blockade (ICB), one of the most transformative advances in oncology. Consequently, the majority of patients with advanced CRC cannot benefit from immunotherapy, representing a major unmet clinical need. INFLAME-TME proposes a novel strategy to overcome this limitation by converting immunologically “cold” MSS tumors into ICB-responsive lesions through targeted induction of tumor-intrinsic immunogenic stress.
Building on discoveries from the ERC AdG PLASTICAN, we identified a previously unrecognized target that is responsible for mitotic spindle assembly while its downregulation causes chromosome missegregation, micronucleus formation, and activation of the cGAS/STING innate immune pathway. In preclinical models of MSS CRC, depletion induces strong CD8⁺ T cell infiltration and sensitizes tumors to ICB. To translate this discovery into a therapeutic strategy, we developed a targeted RNA-based approach aiming to impair tumor cell division while triggering innate immune activation within the tumor microenvironment. INFLAME-TME will assess the technical feasibility and translational potential of this strategy. Key objectives include validating mitotic disruption and cGAS/STING activation, evaluating ICB sensitization, and defining the intellectual property, regulatory, and commercialization paths for further development.
If successful, INFLAME-TME will establish a new paradigm in cancer immunotherapy where targeted RNA delivery induces tumor-intrinsic immunogenicity to overcome ICB resistance. Beyond CRC, this concept could open opportunities for RNA-based immunomodulatory therapies across diverse immunotherapy-resistant malignancies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2026-POC

See all projects funded under this call

Host institution

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG
Net EU contribution
€ 150 000,00
Address
PAUL EHRLICH STRASSE 42-44
60596 FRANKFURT
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)